TN2013000387A1 - T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 - Google Patents
T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2Info
- Publication number
- TN2013000387A1 TN2013000387A1 TNP2013000387A TN2013000387A TN2013000387A1 TN 2013000387 A1 TN2013000387 A1 TN 2013000387A1 TN P2013000387 A TNP2013000387 A TN P2013000387A TN 2013000387 A TN2013000387 A TN 2013000387A TN 2013000387 A1 TN2013000387 A1 TN 2013000387A1
- Authority
- TN
- Tunisia
- Prior art keywords
- antibodies
- hla
- conjugates
- chimeric
- leukemia
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 title 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 2
- 102000025171 antigen binding proteins Human genes 0.000 abstract 2
- 108091000831 antigen binding proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000008383 Wilms tumor Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000025113 myeloid leukemia Diseases 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161491392P | 2011-05-31 | 2011-05-31 | |
| PCT/US2012/031892 WO2012135854A2 (en) | 2011-04-01 | 2012-04-02 | Antibodies to cytosolic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2013000387A1 true TN2013000387A1 (en) | 2015-01-20 |
Family
ID=52395383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2013000387A TN2013000387A1 (en) | 2011-05-31 | 2013-09-26 | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 |
Country Status (1)
| Country | Link |
|---|---|
| TN (1) | TN2013000387A1 (en) |
-
2013
- 2013-09-26 TN TNP2013000387A patent/TN2013000387A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013502043A1 (en) | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 | |
| WO2016191246A3 (en) | T cell receptor-like antibodies specific for a prame peptide | |
| PH12019500603A1 (en) | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof | |
| MX369148B (en) | Kir3dl2 binding agents. | |
| MX2024007724A (en) | Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates | |
| MX2018010331A (en) | Vegf/dll4 binding agents and uses thereof. | |
| BR112012021941A2 (en) | Therapeutic dll4 binding proteins | |
| MX2013011706A (en) | Novel egfr binding proteins. | |
| MX2020004410A (en) | Antibody compositions for tumor treatment. | |
| TN2014000148A1 (en) | Antigen binding protein and its use as addressing product for the treatment of cancer | |
| IN2014MN00873A (en) | ||
| UA95068C2 (en) | Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof | |
| EA201390328A1 (en) | NEW ANTIGENS-BINDING PROTEINS | |
| IN2014CN03936A (en) | ||
| MX2009009450A (en) | He4 monoclonal antibodies and methods for their use. | |
| BR112018008983A2 (en) | asct2-specific binding molecules and their uses | |
| EP2579895A4 (en) | Anti-vegf antibodies and uses thereof | |
| MX2011009220A (en) | Fully human antibodies specific to cadm1. | |
| HK1255815A1 (en) | Compositions and methods for treating peritoneal cancers | |
| TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
| MX2022005718A (en) | Tmem219 antibodies and therapeutic uses thereof. | |
| TN2013000387A1 (en) | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 | |
| EA202090303A3 (en) | ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS | |
| UA108207C2 (en) | HIGH-AFIN HUMAN ANTIBODY TO HUMAN ANGIOPOETIN-2 |